Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant increase in stock price, rising over 6% and reaching a trading price of 2.79 HKD, with a transaction volume of 1.72 million HKD [1] Group 1: Share Placement Announcement - Beihai Kangcheng announced a placement of 84.036 million shares to a subsidiary of WuXi Biologics, representing approximately 14.12% of the enlarged share capital [1] - The net proceeds from the share placement are approximately 199 million HKD, with 12% allocated for operational funds and regulatory maintenance of commercialized products, 28% for research and development expenses of existing product lines, and 60% for settling trade payables of the group [1] - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]
港股异动 北海康成-B(01228)午后涨超6% 拟向药明生物子公司配股 净筹约1.99亿港元